Home Learn BPC-157

BPC-157: Body Protection Compound

12 min read Research Overview Updated March 2026

BPC-157, a pentadecapeptide derived from human gastric juice, has emerged as one of the most extensively studied peptides in preclinical research. Its broad range of observed effects across multiple biological systems has generated significant scientific interest over the past two decades.

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a naturally occurring protective protein found in human gastric juice. The sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — has been the subject of extensive preclinical investigation since its initial characterization in the early 1990s.

Unlike many bioactive peptides that degrade rapidly under physiological conditions, BPC-157 has demonstrated notable stability in human gastric juice, a characteristic that distinguishes it from other peptides in research. This stability has contributed to sustained scientific interest in its potential biological activities.

Key Identifier

Peptide Profile

Full Name: Body Protection Compound-157
Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Molecular Weight: 1,419.53 g/mol
CAS Number: 137525-51-0
Classification: Gastric pentadecapeptide

Mechanism of Action

The mechanisms underlying BPC-157's observed biological activities are multifaceted and remain an active area of investigation. Research has identified several key pathways through which BPC-157 appears to exert its effects.

Nitric Oxide (NO) System Modulation

Studies suggest that BPC-157 interacts with the nitric oxide (NO) system, which plays a central role in vascular function, inflammation, and tissue homeostasis. Research indicates the peptide may modulate NO synthase activity, potentially influencing blood flow and vascular tone at sites of tissue disruption.

Growth Factor Upregulation

Preclinical data suggest BPC-157 may influence the expression of several growth factors relevant to tissue repair processes. Research has observed effects on vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and other factors involved in angiogenesis — the formation of new blood vessels from existing vasculature.

FAK-Paxillin Pathway

Studies have examined BPC-157's interaction with the FAK-paxillin pathway, which is involved in cellular adhesion, migration, and proliferation. This pathway plays a significant role in how cells respond to extracellular signals and is relevant to wound healing processes.

Dopaminergic System Interaction

Research has explored BPC-157's influence on the dopaminergic system, with studies observing effects on dopamine receptor expression and turnover. This area of investigation has generated interest regarding the peptide's potential relevance to central nervous system research.

Research Overview

BPC-157 has been investigated in over 100 preclinical studies across a wide range of biological models. The following table summarizes key areas of published research.

Research Area Key Findings Study Type
Gastrointestinal Studies have observed cytoprotective effects on gastric mucosa and modulatory effects on gut-brain axis signaling In vivo (rodent)
Musculoskeletal Research suggests accelerated tendon-to-bone healing and enhanced recovery in transected tendon models In vivo (rodent)
Vascular Observed promotion of angiogenesis and improved blood vessel formation in preclinical models In vivo / In vitro
Neuroprotective Studies have reported modulatory effects on dopamine and serotonin systems with potential neuroprotective observations In vivo (rodent)
Wound Healing Research indicates enhanced wound closure rates and fibroblast proliferation in skin wound models In vivo (rodent)
Hepatoprotective Preclinical models have observed protective effects against alcohol-induced and NSAID-induced liver damage In vivo (rodent)
Research Context

The majority of BPC-157 research has been conducted in rodent models. While the breadth of preclinical findings is notable, human clinical trial data remains limited. Results from animal studies do not necessarily translate directly to human outcomes, and further clinical investigation is needed.

Common Areas of Research Interest

Scientific interest in BPC-157 spans multiple research domains. The following areas represent the most actively investigated applications in the published literature.

Pharmacokinetics

Pharmacokinetic data on BPC-157 remains limited relative to the breadth of efficacy studies. The available literature provides the following general parameters, though detailed human pharmacokinetic profiling has not been extensively published.

~4h
Estimated Half-Life
Stable
Gastric Juice Stability
1,419
Molecular Weight (Da)
15
Amino Acid Residues

A distinguishing pharmacokinetic feature of BPC-157 is its stability in human gastric juice. Unlike many peptides that are rapidly degraded by gastric enzymes and low pH, BPC-157 has demonstrated resistance to degradation under these conditions, a property that has been highlighted across multiple studies as potentially relevant to oral bioavailability.

Comparison to Similar Peptides

BPC-157 is often discussed alongside other peptides studied in similar research contexts. The following comparison highlights key distinctions.

Feature BPC-157 TB-500 (Thymosin Beta-4) GHK-Cu
Origin Human gastric juice Thymus gland Human plasma (naturally occurring)
Primary Research Focus GI protection, musculoskeletal, neuroprotection Cardiac, wound healing, inflammation Skin remodeling, anti-aging, wound healing
Amino Acids 15 43 3 (tripeptide + copper)
Gastric Stability High Low Moderate
Key Mechanism NO system, growth factor upregulation Actin sequestration, cell migration Copper delivery, collagen synthesis
Research Volume 100+ preclinical studies 50+ preclinical studies 70+ studies (preclinical + clinical)

Frequently Asked Questions

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protein found naturally in human gastric juice. Its name — Body Protection Compound — reflects early research observations regarding its cytoprotective properties. The peptide was first characterized by researchers investigating the protective mechanisms of gastric secretions.
BPC-157 has been studied across a wide range of preclinical models including gastrointestinal, musculoskeletal, neurological, vascular, and organ protection research. The peptide has been investigated in over 100 published studies, primarily in rodent models. Research has explored its effects on tissue repair processes, angiogenesis, neurotransmitter modulation, and cytoprotection.
While both peptides have been studied in the context of tissue recovery, they differ significantly in origin, structure, and mechanism. BPC-157 is a 15-amino acid peptide derived from gastric juice that primarily interacts with the NO system and growth factors. TB-500 (Thymosin Beta-4) is a larger 43-amino acid peptide from the thymus that works primarily through actin sequestration and cell migration. BPC-157 has also demonstrated notably higher gastric stability compared to TB-500.
BPC-157 is not currently approved by the FDA or equivalent regulatory agencies for any therapeutic use in humans. The existing research base consists primarily of preclinical (animal model) studies and in vitro investigations. BPC-157 is available for research purposes. Any human application would require further clinical trials and regulatory review.
Several characteristics distinguish BPC-157 in the research literature. Its stability in human gastric juice is unusual among bioactive peptides, most of which degrade rapidly under acidic conditions. The breadth of its studied effects — spanning gastrointestinal, musculoskeletal, neurological, vascular, and hepatoprotective domains — is also notable. Additionally, the consistency of positive findings across diverse experimental models has sustained scientific interest over more than two decades.
Published research on BPC-157 is available through peer-reviewed databases including PubMed (pubmed.ncbi.nlm.nih.gov), Google Scholar, and specific journals such as the Journal of Physiology, Life Sciences, and the Journal of Pharmacological Sciences. Searching "BPC-157" or "pentadecapeptide BPC 157" on these platforms will return the full body of published literature.

Sources & References

  1. Sikiric P, et al. "Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications." Current Neuropharmacology. 2016;14(8):857-865. PubMed
  2. Seiwerth S, et al. "BPC 157 and blood vessels." Current Pharmaceutical Design. 2014;20(7):1014-1025. PubMed
  3. Chang CH, et al. "BPC-157 enhances the growth hormone receptor expression in tendon fibroblasts." Molecules. 2020;25(20):4700. PubMed
  4. Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157—NO system relation." Current Pharmaceutical Design. 2014;20(7):1126-1135. PubMed
  5. Staresinic M, et al. "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth." Journal of Orthopaedic Research. 2003;21(6):976-983. PubMed
  6. Sikiric P, et al. "Pentadecapeptide BPC 157 interactions with dopamine and GABA systems." Current Medicinal Chemistry. 2020;27(19):3467-3481.
  7. Tkalcevic VI, et al. "Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression." European Journal of Pharmacology. 2007;570(1-3):212-221. PubMed
  8. Sikiric P, et al. "The pharmacological properties of the novel peptide BPC 157 (PL-10, PLD-116, PL 14736)." Inflammopharmacology. 1999;7(1):1-14.

Explore BPC-157

Available for research purposes. Third-party tested for purity and identity.

View BPC-157 Products

This product is intended for research and laboratory use only. It is not intended for human consumption.

Disclaimer: This content is provided for educational and informational purposes only. It is not intended as medical advice, nor does it constitute a recommendation for the treatment, cure, or prevention of any disease or condition. BPC-157 is sold for research purposes only and is not intended for human consumption. Always consult a qualified healthcare professional before making decisions about your health. Somata Peptides does not claim that any products treat, cure, or prevent any disease.